Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...

The scientists demonstrate that it is possible to specifically deliver the treatment to the muscle stem cells, avoiding ...

YolTech's gene therapy is intended as a one-time life-long cure for patients living with PH1, which can lead to kidney ...

Aamal Company posted a net profit of QR432.5mn in 2024, up 17.7% on the previous year, the company announced on Tuesday. The ...

The FDA has lifted its hold and has given Entrada Therapeutics permission to launch a Phase 1b clinical trial to test ...

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...